<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26886">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084615</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0976</org_study_id>
    <nct_id>NCT02084615</nct_id>
  </id_info>
  <brief_title>Prospective Study Comparing Aspirin Versus Placebo and Blood Loss in Inguinal Hernia Repair</brief_title>
  <official_title>A Prospective, Randomized, Double-blinded Study Comparing the Use of Aspirin Versus Placebo and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jesse Brown VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jesse Brown VA Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aspirin administered in the perioperative
      period will increase the blood loss associated with open inguinal hernia repairs.  A
      secondary purpose of this study is to determine if the aspirin administered in the
      perioperative period increases the risk of complications associated with open inguinal
      hernia repairs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blinded study which compares the use of 81mg of
      aspirin, 325mg of aspirin and placebo in adult men undergoing an open tension free mesh
      inguinal hernia repair. Subjects will be randomized to one of the three groups
      preoperatively.  Study medication will be administered for 7 days preoperatively and 7 days
      postoperatively.  Intraoperative blood loss will be measured utilizing a gravimetric method
      by weighing surgical sponges before and after use.  Subjects will be followed for thirty
      days postoperatively and be evaluated for bleeding complications. The specific complications
      include wound or scrotal hematomas, return to the operating room within 72 hour for
      bleeding, wound infection, early recurrent hernia, excessive wound ecchymosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>intraoperative only</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>intraoperative blood loss will be accurately measured among the three arms of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>30 days post operative</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects will be followed for 30 days post-operatively for bleeding complications such as early return to the operating room to control bleeding, wound hematoma, scrotal hematoma, wound infection, early hernia recurrence, or excessive wound ecchymosis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">203</enrollment>
  <condition>Hernia, Inguinal</condition>
  <condition>Postoperative Complications</condition>
  <condition>Postoperative Hemorrhage</condition>
  <arm_group>
    <arm_group_label>81mg aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to one of three arms.  This arm will include perioperative 81 mg of aspirin for 7 days preoperatively and 7 days postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>325mg aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to 325mg of aspirin for 7 days preoperatively and 7 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to the placebo arm and receive no aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Subjects will be randomized to receive either 81mg of aspirin, 325mg of aspirin or placebo</description>
    <arm_group_label>81mg aspirin</arm_group_label>
    <arm_group_label>325mg aspirin</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized to aspirin or  a placebo arm</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult male veterans ages 18-99

          -  inguinal hernia

        Exclusion Criteria:

          -  recurrent hernia

          -  &quot;giant&quot; hernia

          -  women

          -  known allergy or adverse reaction to aspirin

          -  known allergy to non steroidal anti-inflammatory drugs

          -  active peptic ulcer disease

          -  heavy alcohol use (greater than 5 drinks/day)

          -  International Normalized Ratio &gt; 1.7

          -  Hemophilia or other know congenital bleeding disorder

          -  Subject currently taking aspirin with history of prior cerebral vascular accident

          -  Subject with known cardiac, coronary, carotid or other vascular stents on aspirin
             therapy

          -  Subjects currently on aspirin therapy under the advise of a physician where
             withdrawal of aspirin therapy could be hazardous

          -  severe renal insufficiency (GFR &lt; 10 mL/min)

          -  Cirrhosis of hepatitis with coagulopathy

          -  Thrombocytopenia with platelet counts &lt; 100,000

          -  Subjects currently on Coumadin or other platelet inhibitors
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph M Vitello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jesse Brown VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph M Vitello, MD</last_name>
    <phone>630-234-8214</phone>
    <email>joseph.vitello@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph M Vitello, MD</last_name>
      <phone>630-234-8214</phone>
      <email>joseph.vitello@va.gov</email>
    </contact>
    <investigator>
      <last_name>Dominic J Vitello</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Antolovic D, Rakow A, Contin P, Ulrich A, Rahbari NN, BÃ¼chler MW, Weitz J, Koch M. A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007). Langenbecks Arch Surg. 2012 Feb;397(2):297-306. doi: 10.1007/s00423-011-0867-7. Epub 2011 Nov 3.</citation>
    <PMID>22048442</PMID>
  </reference>
  <reference>
    <citation>Binhas M, Salomon L, Roudot-Thoraval F, Armand C, Plaud B, Marty J. Radical prostatectomy with robot-assisted radical prostatectomy and laparoscopic radical prostatectomy under low-dose aspirin does not significantly increase blood loss. Urology. 2012 Mar;79(3):591-5. doi: 10.1016/j.urology.2011.11.031.</citation>
    <PMID>22386405</PMID>
  </reference>
  <reference>
    <citation>Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005 May;257(5):399-414. Review.</citation>
    <PMID>15836656</PMID>
  </reference>
  <reference>
    <citation>Chechik O, Goldstein Y, Behrbalk E, Kaufman E, Rabinovich Y. Blood loss and complications following carotid endarterectomy in patients treated with clopidogrel. Vascular. 2012 Aug;20(4):193-7. doi: 10.1258/vasc.2011.oa0336. Epub 2012 May 10.</citation>
    <PMID>22577162</PMID>
  </reference>
  <reference>
    <citation>Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg. 2012 May;255(5):811-9. doi: 10.1097/SLA.0b013e318250504e. Review.</citation>
    <PMID>22470078</PMID>
  </reference>
  <reference>
    <citation>Kang SB, Cho KJ, Moon KH, Jung JH, Jung SJ. Does low-dose aspirin increase blood loss after spinal fusion surgery? Spine J. 2011 Apr;11(4):303-7. doi: 10.1016/j.spinee.2011.02.006.</citation>
    <PMID>21474081</PMID>
  </reference>
  <reference>
    <citation>Leyh-Bannurah SR, Hansen J, Isbarn H, Steuber T, Tennstedt P, Michl U, Schlomm T, Haese A, Heinzer H, Huland H, Graefen M, BudÃ¤us L. Open and robotic assisted radical retropubic prostatectomy in men with ongoing low-dose aspirin medication: revisiting old paradigm? BJU Int. 2013 Oct 15. doi: 10.1111/bju.12504. [Epub ahead of print]</citation>
    <PMID>24127902</PMID>
  </reference>
  <reference>
    <citation>Madan GA, Madan SG, Madan G, Madan AD. Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients. J Oral Maxillofac Surg. 2005 Sep;63(9):1262-5.</citation>
    <PMID>16122588</PMID>
  </reference>
  <reference>
    <citation>Manning BJ, O'Brien N, Aravindan S, Cahill RA, McGreal G, Redmond HP. The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury. 2004 Feb;35(2):121-4.</citation>
    <PMID>14736467</PMID>
  </reference>
  <reference>
    <citation>Ono K, Idani H, Hidaka H, Kusudo K, Koyama Y, Taguchi S. Effect of aspirin continuation on blood loss and postoperative morbidity in patients undergoing laparoscopic cholecystectomy or colorectal cancer resection. Surg Laparosc Endosc Percutan Tech. 2013 Feb;23(1):97-100. doi: 10.1097/SLE.0b013e318278cdf8.</citation>
    <PMID>23386161</PMID>
  </reference>
  <reference>
    <citation>Oscarsson A, Gupta A, Fredrikson M, JÃ¤rhult J, NystrÃ¶m M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010 Mar;104(3):305-12. doi: 10.1093/bja/aeq003.</citation>
    <PMID>20150346</PMID>
  </reference>
  <reference>
    <citation>Partridge CG, Campbell JH, Alvarado F. The effect of platelet-altering medications on bleeding from minor oral surgery procedures. J Oral Maxillofac Surg. 2008 Jan;66(1):93-7.</citation>
    <PMID>18083421</PMID>
  </reference>
  <reference>
    <citation>Zigdon H, Levin L, Filatov M, Oettinger-Barak O, Machtei EE. Intraoperative bleeding during open flap debridement and regenerative periodontal surgery. J Periodontol. 2012 Jan;83(1):55-60. doi: 10.1902/jop.2011.110182. Epub 2011 May 12.</citation>
    <PMID>21563946</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>March 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jesse Brown VA Medical Center</investigator_affiliation>
    <investigator_full_name>Joseph Vitello, MD</investigator_full_name>
    <investigator_title>Chief, General Surgery</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Postoperative hemorrhage</keyword>
  <keyword>Inguinal hernia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
